MedTrace Logo

Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO

NCT04879550 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-05-24

No results posted yet for this study

Summary

There are publications showing a decrease in Antithrombin III levels of continuous flow and routine heparin therapy in adult patients undergoing Extracorporeal Membrane Oxygenation (ECMO) however, there is not enough data. One of the multifactorial causes affecting bleeding / thrombosis complications and ACT levels may be acquired Antithrombin III deficiency.

The Antithrombin III activity test results from the patients to be included in the study during the study will be recorded immediately after ECMO run, at the 24th hour before the heparin infusion start and at the 48th, 72nd and 96th hours following the follow-up. The results will be analyzed to figure out a relationship between decreasing Antithrombin 3 values and thrombotic events.

Conditions

  • Antithrombin III Deficiency
  • Extracorporeal Membrane Oxygenation Complication

Interventions

DIAGNOSTIC_TEST

Antithrombin III

Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.

Sponsors & Collaborators

  • Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital

    lead OTHER

Principal Investigators

  • Serap AKA · Cardiovascular Surgeon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-01-01
Completion
2022-03-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04879550 on ClinicalTrials.gov